While this is certainly unprecedented for me, I’ve requested @eatmostlyfatali allow me to change my talk at Low Carb Houston to accommodate some Big Announcements I will soon be able to share, and he’s accepted.
In many ways, this will be unlike any talk I’ve done before or will likely do again. It will be much more like a TED talk, with a lot less slides and a lot more concise statements, summarizing my work to date and some key considerations I’d like to share.
All of which will tie in nicely to the announcements, and some very important next steps.
As they say… it’s a blessing to live in interesting times…
At the upcoming conference, Low Carb Houston, on October 24-26th we’ll be hosting a blood testing drive where anyone can get their blood taken right there on site for a comprehensive set of tests:
C-Peptide
CBC With Differential/Platelet
Comp. Metabolic Panel (14)
Fatty Acids, Free (Nonesterified)
Ferritin, Serum
GGT
Glucagon
Hemoglobin A1c
High sensitivity C-Reactive Protein (hsCRP)
Insulin
Lipoprotein (a)
Nuclear Magnetic Resonance (NMR)
We’ve managed to negotiate a bulk rate price of $297 per person and the results will be analyzed at Labcorp to be returned in one to two weeks from the blood draw.
While we are excited to provide these services for those who can’t easily get these tests done, a major motivator for this drive is getting more data for the benefit of the community, which is why you are given the option to provide your anonymized results to our pool, which we hope you’ll take. If you follow my work, you know how important I consider open source data for the advancement of science (this is especially important for the LC community). But, again, it’s your option either way and we appreciate the consideration.
As CholesterolCode continues to grow, our ability to handle all the comments coming in has been a concern, but we didn’t want to miss the opportunity to answer the awesome questions you guys have either. Luckily, not too long ago, Low Carb San Diego happened…
Introducing Debbie
At Low Carb San Diego, I met Debbie – she used to be an engineer in silicon valley for 33 years, but is currently retired. She also happened to mention that she was interested in helping out Dave and I, and had the time to offer. She is passionate about learning as much as possible, and helping to get people accurate information so they can make informed decisions, and I felt that this attitude was a good fit, and her help might be a possible solution to our dilemma.
A Warm Welcome
If you haven’t guessed already, all of this is leading to introducing Debbie to the CholesterolCode readerbase! Debbie will be helping out by answering some of the comments that come in starting this week. I’ll still be replying to many of the comments that come in, as per usual, but don’t be surprised if you see Debbie around as well. This will hopefully mean, over time, even faster responses to comments especially during conferences as we continue to grow.
Note from producer: In the efficacy and safety statement for the trial mentioned it lists Merck Sharp & Dohme (manufacturers of simvastatin) as well as Hoffmann-La Roche (manufacturers of the vitamins used) as providing partial funding for the study:
The study is being funded by the UK Medical Research Council, the British Heart Foundation, Merck Sharp & Dohme (manufacturers of simvastatin[…]) and Hoffmann-La Roche (manufacturers of the vitamins[…])
However in the published paper of the results it states the following:
The Clinical Trial Service Unit has a staff policy of not accepting honoraria or other payments from the pharmaceutical industry, except for the reimbursement of costs to participate in scientific meetings.
44:56 If there were a trial that showed that people with
high HDL, high LDL, and low triglycerides didn’t benefit from statins would
[Ethan] want to know that information?
52:40 Open data, machine learning, and possibilities moving
forward
56:20 Non-HDL and mortality from the NHANES dataset
Twitter exchange mentioned:
1/ So here's some "realtime science" for you… @ethanjweiss pinged me in another thread regarding non-HDL regarding risk here: https://t.co/brFpCiXDpa I realized I hadn't actually checked out non-HDL in NHANES to this point. The raw results are pretty interesting…
58:30 Changes in ability to connect with researchers and
scientists
1:00:05 What does Dave mean by risk?
1:04:10 Modifications to low carb to achieve lower LDL
1:08:55 What Dave has learned about the importance of
rigorousness in self-experimentation
1:13:29 Can self-experiments have benefits applicable to
people beyond the person doing them?
1:17:29 Cholesterol biosynthesis
1:18:40 Reverse causality – is there a possibility that the
lipoproteins are reflecting a problem and not causing it?
Note from producer: I attempted a follow-up to see if
I could find any studies looking at the impact of infusion of native mouse
lipoproteins on atherosclerosis development, but I have not found any thus far.
1:24:33 Clotting, vascular injury, and engineering
My primary costs are the many frequent and expensive blood tests I take for this research and data. Any size donation is appreciated. Thank you for your support!
Recent Comments